Developer docs
API playgroundTry for free, no card

Search company profiles

Imbed Biosciences

Full company profile

uuid00006tu

Namestring
Imbed Biosciences
Legal namestring
Imbed Biosciences Inc.
Websiteurl
imbedbio.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Imbed Biosciences Inc. is a privately held medical device company headquartered in Middleton, Wisconsin, founded by physicians and scientists from the University of Wisconsin-Madison. The company develops and commercializes the SAMatrix™ Technology platform — an ultra-thin, fully synthetic, bioresorbable polymeric fiber matrix that integrates antimicrobial silver and (in PainGuard™ variants) lidocaine HCl for combined infection control and non-opioid pain management. Its commercial product family comprises Microlyte® (chronic wounds, including diabetic foot, venous leg, and pressure ulcers), Surgaflex™ (surgical and acute wounds), Pelashield® (burn and acute wounds), and PainGuard™ lidocaine variants of each, supplemented by a veterinary product line. The company has secured FDA 510(k) clearances for the portfolio (including Microlyte Ag/Lidocaine in 2024) and a dedicated CMS HCPCS Level II Code A2040 for Microlyte PainGuard effective April 2026.

Imbed earns revenue through one-time medical device sales of its FDA-cleared wound matrices, distributed primarily through an independent distributor network supplemented by direct sales to enterprise accounts at burn centers, wound centers, hospitals, ASCs, HOPDs, and physician offices. Channel reach is extended via a 2024 GPO agreement with Premier, Inc. and a 2026 strategic investment and distribution partnership with BioLab Holdings targeting physician office and outpatient settings. The GTM motion combines sales-led efforts with channel partners, supported by clinical education through the company-hosted Zero Zone Podcast, clinical webinars, conference participation (ABA, SAWC, Boswick, regional burn conferences), and provider/patient testimonials. Pricing is not publicly disclosed; quotes go through distributors or direct contact.

The company has raised approximately $22M+ since founding across multiple small rounds, an $800K NIH SBIR/NIAMS grant in 2021, a $10M Niterra-led convertible note in January 2024, and an undisclosed BioLab Holdings strategic investment in early 2026. Headcount is in the 11-50 range, consistent with an early-commercial-stage medical device company that is operating, actively executing on its regulatory and reimbursement roadmap, and currently concentrated on U.S. commercialization.

Short descriptiontext

Imbed Biosciences is a privately held medical device company that develops and sells the SAMatrix™ Technology platform — FDA-cleared synthetic antimicrobial wound matrices (Microlyte®, Surgaflex™, Pelashield® and PainGuard™ lidocaine variants) — to U.S. burn centers, wound centers, hospitals, ASCs, HOPDs, and physician offices via distributors and direct sales.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMiddleton, United States
HQ citystring
Middleton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
antimicrobial wound matrix, synthetic skin substitute, advanced wound care, burn care dressings, surgical wound management
Industry4 codes
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAHALAD
Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
NAICS code1 code
  • Surgical Appliance and Supplies Manufacturing339113
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Advanced Wound Care Medical Devices
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Wound Care Product Sales
TypeOne Time License
Description

Imbed Biosciences generates revenue through the sale of FDA-cleared antimicrobial wound matrix products including Microlyte®, Surgaflex™, Pelashield®, and their PainGuard™ variants with lidocaine. Products are sold through a distributor network to healthcare facilities including burn centers, wound centers, hospitals, physician offices, ASCs, and HOPDs.

imbedbio.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1SAMatrix™ Technology
Description

The company's platform technology integrating multiple wound care agents into an ultra-thin, fully synthetic matrix composed of bioresorbable fibers.

imbedbio.com
+4 more records
Core offering1 text field

Imbed Biosciences develops and sells FDA-cleared, fully synthetic antimicrobial wound matrices under its proprietary SAMatrix™ Technology platform. The product portfolio includes Microlyte® for chronic wounds, Surgaflex™ for surgical wounds, and Pelashield® for burn and acute wounds, with PainGuard™ variants adding lidocaine HCl for localized non-opioid pain management. Products are sold to healthcare facilities including burn centers, wound centers, hospitals, physician offices, ASCs, and HOPDs through independent distributors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Sustained antimicrobial activity for up to 3 days demonstrated against broad spectrum of microbes
+2 more records
Product overview1 text field

Imbed Biosciences offers a portfolio of synthetic antimicrobial wound matrices under the SAMatrix™ Technology platform. The product family includes Microlyte® (for chronic wounds), Surgaflex™ (for surgical wounds), and Pelashield® (for burn and acute wounds), with antimicrobial silver integrated into each matrix. The portfolio also includes PainGuard variants (Microlyte® PainGuard™, Surgaflex™ PainGuard™, and Pelashield® PainGuard™) that additionally incorporate lidocaine HCl to manage pain along with bioburden reduction. These brands are indicated across a wide range of chronic and acute wounds, including ulcers, surgical, traumatic, and burn wounds.

Product and service7 records
1Microlyte®
2Surgaflex™
3Pelashield®
4Microlyte® PainGuard™
5Surgaflex™ PainGuard™
6Pelashield® PainGuard™
7Microlyte® VET
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-02-01
Description

Imbed Biosciences was awarded a Skin Integrity and Wound Care agreement with Premier, Inc., a healthcare improvement company. This GPO agreement provides Premier members access to Imbed's wound care products, facilitating purchasing through Premier's network.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global medical device leader with a sizable Advanced Wound Management portfolio (e.g., ALLEVYN, PICO). Directly comparable to Imbed as a competitor in advanced wound dressings and antimicrobial matrices across the same hospital, ASC, and outpatient channels.

TypeBroad incumbent
Description

Major wound care and skin health franchise covering advanced dressings, negative pressure wound therapy, and skin integrity solutions. Competes head-to-head with Imbed in antimicrobial and advanced wound dressings across U.S. hospitals and outpatient settings.

TypeBroad incumbent
Description

Specialist in advanced wound care, ostomy, and continence care with AQUACEL and Foam dressing lines. Highly comparable in distribution channels (HOPDs, wound centers, ASCs) and product overlap with Imbed's Microlyte and Surgaflex matrices.

TypeBroad incumbent
Description

Global wound care and surgical solutions company with Mepilex, Mepitel, and other advanced dressings used in burn and surgical wound care. Directly competes with Imbed's Pelashield and Surgaflex lines in burn centers and OR settings.

TypeBroad incumbent
Description

Danish med-tech with a sizable wound and skin care business (Biatain, Comfeel). Comparable to Imbed in advanced wound dressings for chronic wounds (DFUs, VLUs, pressure ulcers) sold through similar outpatient and home care channels.

TypeDirect peer
Description

Regenerative medicine company specializing in advanced wound care and skin substitutes (Apligraf, Dermagraft, PuraPly). Closely comparable to Imbed as a U.S. skin-substitute and chronic-wound competitor selling under similar HCPCS reimbursement pathways.

TypeDirect peer
Description

Regenerative wound care and surgical recovery company using placental tissue allografts (EpiFix, AmnioFix). Direct competitor to Imbed in the U.S. skin substitute market with similar outpatient and HOPD customer base.

TypeDirect peer
Description

Specialty med-tech focused on regenerative tissue technologies and wound care (Integra Dermal Regeneration Template, PriMatrix). Comparable to Imbed in surgical and burn wound matrix technology and hospital channel sales.

TypeDirect peer
Description

Biotherapeutic wound care franchise (now part of Smith+Nephew) focused on enzymatic debridement and bioactive wound therapies such as Santyl. Comparable to Imbed as a specialized wound-care product company now operating within a major incumbent.

TypeOthers
Description

Major U.S. medical products distributor supplying hospitals, ASCs, and physician offices. Relevant ecosystem participant for Imbed because it represents a potential distributor channel and competes indirectly for wound care formulary space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Imbed Biosciences

Advanced Wound Care Medical Devicesimbedbio.com

Imbed Biosciences is a privately held medical device company that develops and sells the SAMatrix™ Technology platform — FDA-cleared synthetic antimicrobial wound matrices (Microlyte®, Surgaflex™, Pelashield® and PainGuard™ lidocaine variants) — to U.S. burn centers, wound centers, hospitals, ASCs, HOPDs, and physician offices via distributors and direct sales.

What Imbed Biosciences does

Imbed Biosciences Inc. is a privately held medical device company headquartered in Middleton, Wisconsin, founded by physicians and scientists from the University of Wisconsin-Madison. The company develops and commercializes the SAMatrix™ Technology platform — an ultra-thin, fully synthetic, bioresorbable polymeric fiber matrix that integrates antimicrobial silver and (in PainGuard™ variants) lidocaine HCl for combined infection control and non-opioid pain management. Its commercial product family comprises Microlyte® (chronic wounds, including diabetic foot, venous leg, and pressure ulcers), Surgaflex™ (surgical and acute wounds), Pelashield® (burn and acute wounds), and PainGuard™ lidocaine variants of each, supplemented by a veterinary product line. The company has secured FDA 510(k) clearances for the portfolio (including Microlyte Ag/Lidocaine in 2024) and a dedicated CMS HCPCS Level II Code A2040 for Microlyte PainGuard effective April 2026.

Imbed earns revenue through one-time medical device sales of its FDA-cleared wound matrices, distributed primarily through an independent distributor network supplemented by direct sales to enterprise accounts at burn centers, wound centers, hospitals, ASCs, HOPDs, and physician offices. Channel reach is extended via a 2024 GPO agreement with Premier, Inc. and a 2026 strategic investment and distribution partnership with BioLab Holdings targeting physician office and outpatient settings. The GTM motion combines sales-led efforts with channel partners, supported by clinical education through the company-hosted Zero Zone Podcast, clinical webinars, conference participation (ABA, SAWC, Boswick, regional burn conferences), and provider/patient testimonials. Pricing is not publicly disclosed; quotes go through distributors or direct contact.

The company has raised approximately $22M+ since founding across multiple small rounds, an $800K NIH SBIR/NIAMS grant in 2021, a $10M Niterra-led convertible note in January 2024, and an undisclosed BioLab Holdings strategic investment in early 2026. Headcount is in the 11-50 range, consistent with an early-commercial-stage medical device company that is operating, actively executing on its regulatory and reimbursement roadmap, and currently concentrated on U.S. commercialization.

Imbed Biosciences firmographics

Firmographics
Name
Imbed Biosciences
Legal name
Imbed Biosciences Inc.
Website
https://imbedbio.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Imbed Biosciences is a privately held medical device company that develops and sells the SAMatrix™ Technology platform — FDA-cleared synthetic antimicrobial wound matrices (Microlyte®, Surgaflex™, Pelashield® and PainGuard™ lidocaine variants) — to U.S. burn centers, wound centers, hospitals, ASCs, HOPDs, and physician offices via distributors and direct sales.
Ownership category
akta.pro rank

Imbed Biosciences industry classification

Industry
Product category
Advanced Wound Care Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAA
Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAHALAD
Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products

Keywords

  • Antimicrobial wound matrix
  • Synthetic skin substitute
  • Advanced wound care
  • Burn care dressings
  • Surgical wound management

Where Imbed Biosciences is headquartered

Location

Headquarters

HQ city
Middleton
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Imbed Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Wound Care Product Sales: Imbed Biosciences generates revenue through the sale of FDA-cleared antimicrobial wound matrix products including Microlyte®, Surgaflex™, Pelashield®, and their PainGuard™ variants with lidocaine. Products are sold through a distributor network to healthcare facilities including burn centers, wound centers, hospitals, physician offices, ASCs, and HOPDs.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Imbed Biosciences product offering

Product offering

Core offering

Imbed Biosciences develops and sells FDA-cleared, fully synthetic antimicrobial wound matrices under its proprietary SAMatrix™ Technology platform. The product portfolio includes Microlyte® for chronic wounds, Surgaflex™ for surgical wounds, and Pelashield® for burn and acute wounds, with PainGuard™ variants adding lidocaine HCl for localized non-opioid pain management. Products are sold to healthcare facilities including burn centers, wound centers, hospitals, physician offices, ASCs, and HOPDs through independent distributors.

Product overview

Imbed Biosciences offers a portfolio of synthetic antimicrobial wound matrices under the SAMatrix™ Technology platform. The product family includes Microlyte® (for chronic wounds), Surgaflex™ (for surgical wounds), and Pelashield® (for burn and acute wounds), with antimicrobial silver integrated into each matrix. The portfolio also includes PainGuard variants (Microlyte® PainGuard™, Surgaflex™ PainGuard™, and Pelashield® PainGuard™) that additionally incorporate lidocaine HCl to manage pain along with bioburden reduction. These brands are indicated across a wide range of chronic and acute wounds, including ulcers, surgical, traumatic, and burn wounds.

Differentiator

Problem solved

Functional benefit

Brands

  • SAMatrix™ Technology: The company's platform technology integrating multiple wound care agents into an ultra-thin, fully synthetic matrix composed of bioresorbable fibers.
  • Microlyte®
  • Surgaflex™
  • Pelashield®
  • PainGuard™

Products and services

  • Microlyte®
  • Surgaflex™
  • Pelashield®
  • Microlyte® PainGuard™
  • Surgaflex™ PainGuard™
  • Pelashield® PainGuard™
  • Microlyte® VET

Quantifiable outcome

  • Sustained antimicrobial activity for up to 3 days demonstrated against broad spectrum of microbes
  • +2 more outcomes

Companies that use Imbed Biosciences

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Imbed Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Imbed Biosciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Premier, Inc.coreChannel Partner/ Reseller/ Distributor · 1 February 2024Imbed Biosciences was awarded a Skin Integrity and Wound Care agreement with Premier, Inc., a healthcare improvement company. This GPO agreement provides Premier members access to Imbed's wound care products, facilitating purchasing through Premier's network.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Imbed Biosciences competitors and assessment

Company assessment

Broad incumbents

  • Smith+Nephew: Global medical device leader with a sizable Advanced Wound Management portfolio (e.g., ALLEVYN, PICO). Directly comparable to Imbed as a competitor in advanced wound dressings and antimicrobial matrices across the same hospital, ASC, and outpatient channels.
  • Solventum (formerly 3M Health Care): Major wound care and skin health franchise covering advanced dressings, negative pressure wound therapy, and skin integrity solutions. Competes head-to-head with Imbed in antimicrobial and advanced wound dressings across U.S. hospitals and outpatient settings.
  • ConvaTec: Specialist in advanced wound care, ostomy, and continence care with AQUACEL and Foam dressing lines. Highly comparable in distribution channels (HOPDs, wound centers, ASCs) and product overlap with Imbed's Microlyte and Surgaflex matrices.
  • Mölnlycke Health Care: Global wound care and surgical solutions company with Mepilex, Mepitel, and other advanced dressings used in burn and surgical wound care. Directly competes with Imbed's Pelashield and Surgaflex lines in burn centers and OR settings.
  • Coloplast: Danish med-tech with a sizable wound and skin care business (Biatain, Comfeel). Comparable to Imbed in advanced wound dressings for chronic wounds (DFUs, VLUs, pressure ulcers) sold through similar outpatient and home care channels.

Direct peers

  • Organogenesis: Regenerative medicine company specializing in advanced wound care and skin substitutes (Apligraf, Dermagraft, PuraPly). Closely comparable to Imbed as a U.S. skin-substitute and chronic-wound competitor selling under similar HCPCS reimbursement pathways.
  • MiMedx: Regenerative wound care and surgical recovery company using placental tissue allografts (EpiFix, AmnioFix). Direct competitor to Imbed in the U.S. skin substitute market with similar outpatient and HOPD customer base.
  • Integra LifeSciences: Specialty med-tech focused on regenerative tissue technologies and wound care (Integra Dermal Regeneration Template, PriMatrix). Comparable to Imbed in surgical and burn wound matrix technology and hospital channel sales.
  • Healthpoint Biotherapeutics (Smith+Nephew): Biotherapeutic wound care franchise (now part of Smith+Nephew) focused on enzymatic debridement and bioactive wound therapies such as Santyl. Comparable to Imbed as a specialized wound-care product company now operating within a major incumbent.

Others

  • Cardinal Health: Major U.S. medical products distributor supplying hospitals, ASCs, and physician offices. Relevant ecosystem participant for Imbed because it represents a potential distributor channel and competes indirectly for wound care formulary space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Imbed Biosciences social profiles

Digital presence

Imbed Biosciences compliance and trust

Trust signal

Compliance2 records

Imbed Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Imbed Biosciences leadership team

Management profile

Number of profiles

Profiles6 records

Imbed Biosciences funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Imbed Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Imbed Biosciences

What does Imbed Biosciences do?

Imbed Biosciences develops and sells FDA-cleared, fully synthetic antimicrobial wound matrices under its proprietary SAMatrix™ Technology platform. The product portfolio includes Microlyte® for chronic wounds, Surgaflex™ for surgical wounds, and Pelashield® for burn and acute wounds, with PainGuard™ variants adding lidocaine HCl for localized non-opioid pain management. Products are sold to healthcare facilities including burn centers, wound centers, hospitals, physician offices, ASCs, and HOPDs through independent distributors.

Is Imbed Biosciences a public or private company?

Imbed Biosciences is a private company. It is classified as venture growth investor backed and is currently operating.

When was Imbed Biosciences founded?

Imbed Biosciences was founded in 2012. It employs 11 to 50 people.

Where is Imbed Biosciences based?

Imbed Biosciences is headquartered in Middleton, United States, in the North America region.

How does Imbed Biosciences make money?

One revenue line is on record: wound Care Product Sales.

Who are Imbed Biosciences's main competitors?

Broad incumbents on record are Smith+Nephew, Solventum (formerly 3M Health Care), ConvaTec, Mölnlycke Health Care and Coloplast. Direct peers are Organogenesis, MiMedx, Integra LifeSciences and Healthpoint Biotherapeutics (Smith+Nephew). Cardinal Health is listed as an others.

Does Imbed Biosciences have an API?

No public API is recorded for Imbed Biosciences.

What industry is Imbed Biosciences in?

Imbed Biosciences's product category is Advanced Wound Care Medical Devices. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceImbed Biosciences’ DualGuard™ Silver-Gallium Matrix Safety Study Now Registered on ClinicalTrials.govImbed Biosciences registered its FDA-approved IDE study on DualGuard Silver-Gallium Matrix safety on ClinicalTrials.gov (NCT07695688). The multi-center trial at three burn centers will enroll 53 subjects to evaluate safety and wound closure. It is the first clinical evaluation of gallium in a wound care matrix.PR NewswireImbed Biosciences' DualGuard™ Silver-Gallium Matrix Safety Study Now Registered on ClinicalTrials.govImbed Biosciences registered its FDA-approved IDE study of DualGuard Silver-Gallium Matrix on ClinicalTrials.gov (NCT07695688) for safety evaluation in split-thickness skin graft donor site wounds. The multi-center trial at three ABA-verified burn centers will enroll 53 subjects, with primary objective to assess safety and tolerability.Dermatology TimesImbed Biosciences Receives Technology Breakthrough Designation for PelashieldAM from Premier, IncImbed Biosciences received a Technology Breakthrough designation for its PelashieldAM product from Premier, Inc., recognizing the innovation's advantages in patient safety and clinical outcomes. The agreement, effective February 1, 2024, grants Premier members exclusive pricing and terms to access the pediatric burn care solution.BioSpaceImbed Biosciences Announces CMS Assignment of HCPCS Code A2040 for Microlyte® PainGuard™Imbed Biosciences announced that the Centers for Medicare & Medicaid Services (CMS) has assigned Healthcare Common Procedure Coding System (HCPCS) Level II code A2040 to its Microlyte® PainGuard™ synthetic wound matrix product, effective April 1, 2026. The code enables healthcare providers to report the product on claims submitted to payers recognizing HCPCS Level II codes, representing a step toward billing clarity and claims visibility. Microlyte® PainGuard™ incorporates silver for antimicrobial activity and lidocaine HCl for localized non-opioid pain management, building on Imbed's Synthetic Antimicrobial Matrix Technology platform.AijournImbed Biosciences Announces CMS Assignment of HCPCS Code A2040 for Microlyte® PainGuard™Imbed Biosciences announced that the Centers for Medicare & Medicaid Services (CMS) has assigned HCPCS Level II code A2040 to its Microlyte PainGuard synthetic wound matrix, effective April 1, 2026. The code enables healthcare providers to report the product on claims submitted to payers recognizing Level II codes, supporting billing clarity and claims visibility. Microlyte PainGuard incorporates silver for antimicrobial activity and lidocaine HCl for localized non-opioid pain management in wound care applications.PR NewswireImbed Biosciences Announces CMS Assignment of HCPCS Code A2040 for Microlyte® PainGuard™Imbed Biosciences announced that the Centers for Medicare & Medicaid Services (CMS) has assigned HCPCS Level II code A2040 to Microlyte® PainGuard™, a synthetic wound matrix with antimicrobial silver and localized lidocaine HCl for non-opioid pain management. The code, effective April 1, 2026, enables healthcare providers to report the product on claims submitted to payers recognizing HCPCS Level II codes, supporting billing clarity and administrative efficiency. The company stated this designation helps providers incorporate the product into clinical workflows as they evaluate appropriate use across clinical settings.openPR.comEmerging Sub-Segments Transforming the Bioactive Wound Care Market LandscapeThe Business Research Company released a market report projecting the global bioactive wound care market to reach $12.48 billion by 2030, growing at a compound annual growth rate of 8.5%, driven by nanocrystalline silver and iodine-based dressings, home care expansion, and rising diabetic and aging populations. In October 2024, US-based Imbed Biosciences Inc. received FDA 510(k) clearance for Microlyte Ag, an antimicrobial wound dressing combining silver with lidocaine for pain management and infection control. In May 2025, NovaBone Products LLC, a US biotechnology firm, partnered with Summit Products Group to accelerate distribution of its NovaForm Wound Matrix across outpatient and post-acute care settings in the United States.FinSMEsImbed Biosciences Receives Investment from BioLab HoldingsImbed Biosciences, a privately held medical device company based in Middleton, Wisconsin, received an investment from BioLab Holdings to accelerate development of its SAM Antimicrobial Technology platform. The deal amount was not disclosed. The technology is designed to minimize wound care complications by incorporating multiple therapeutic agents into ultra-thin, biocompatible matrices that support skin regeneration in chronic and acute wounds.PR NewswireImbed Biosciences Secures Strategic Investment from BioLab HoldingsImbed Biosciences announced a strategic investment from BioLab Holdings Inc. to expand its reach in the US market, particularly in medical office settings, and accelerate development of its SAM™ Antimicrobial Technology platform. The investment centers on Imbed's Microlyte® product for chronic wound indications, with Imbed holding a unique market position as the only fully synthetic and antimicrobial skin substitute available. The funding aims to support adoption in physician office settings while helping accelerate wound care solutions that simplify care delivery and improve patient outcomes.PR NewswireImbed Biosciences Launches Dual-Action Wound Matrix Integrating Bioburden Management and Pain Relief in a Single SolutionImbed Biosciences Inc. announced the launch of SAM PainGuard with Lidocaine, a dual-action wound matrix combining antimicrobial silver and lidocaine for pain relief in surgical, burn, and trauma wounds. The FDA 510(k)-cleared product delivers over 80% of lidocaine within the first 30 minutes and provides 72 hours of microbial reduction, addressing a clinical need as nearly 90% of post-surgical patients experience moderate to severe pain. The Surgaflex PainGuard and Pelashield PainGuard products are now commercially available in the U.S. market.